Achilles Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Achilles Therapeutics PLC
ACHL Stock  USD 1.49  0.05  3.47%   
Achilles Therapeutics financial statements provide useful quarterly and yearly information to potential Achilles Therapeutics PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Achilles Therapeutics financial statements helps investors assess Achilles Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Achilles Therapeutics' valuation are summarized below:
Market Capitalization
61.5 M
Earnings Share
(1.66)
There are over one hundred nineteen available fundamental signals for Achilles Therapeutics PLC, which can be analyzed over time and compared to other ratios. We recommend to validate Achilles Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 38.8 M. Enterprise Value is expected to rise to about (99.8 M) this year
Check Achilles Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Achilles Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 8.8 M, Tax Provision of 39.2 K or Depreciation And Amortization of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.27. Achilles financial statements analysis is a perfect complement when working with Achilles Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Achilles Therapeutics Correlation against competitors.

Achilles Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities6.3 M9 M3.2 M
Slightly volatile
Total Current Liabilities13.9 M19.5 M7.5 M
Slightly volatile
Net Tangible Assets173.7 M226.6 M93 M
Slightly volatile
Accounts Payable4 M6.5 M2.1 M
Slightly volatile
Net Receivables9.5 M11.9 M5.8 M
Slightly volatile
Other Current Assets4 M4.3 M2 M
Slightly volatile
Total Current Assets170.7 M167.5 M86 M
Slightly volatile
Property Plant Equipment17.6 M23.6 M9.1 M
Slightly volatile
Total Assets225.1 M185.7 M148.8 M
Slightly volatile
Short and Long Term Debt Total9.2 M5.3 M3.8 M
Slightly volatile
Total Stockholder Equity202.3 M163.7 M137.4 M
Slightly volatile
Property Plant And Equipment Net20.5 M15.6 M9.3 M
Slightly volatile
Cash186.3 M151.3 M128.9 M
Slightly volatile
Non Current Assets Total23.1 M18.2 M10.4 M
Slightly volatile
Non Currrent Assets Other2.6 M2.5 M1.1 M
Slightly volatile
Cash And Short Term Investments186.3 M151.3 M128.9 M
Slightly volatile
Common Stock Total Equity21.4 K28.8 K18.1 K
Slightly volatile
Common Stock Shares Outstanding33 M46 M15.2 M
Slightly volatile
Short Term Investments0.860.9166
Slightly volatile
Liabilities And Stockholders Equity225.1 M185.7 M148.8 M
Slightly volatile
Non Current Liabilities Total1.8 M1.9 M2.9 M
Slightly volatile
Capital Lease Obligations9.2 M5.3 M3.8 M
Slightly volatile
Inventory1.091.151 M
Pretty Stable
Total Liabilities22.7 M22 M11.4 M
Slightly volatile
Net Invested Capital202.3 M163.7 M137.3 M
Slightly volatile
Property Plant And Equipment Gross26 M30.4 M12.1 M
Slightly volatile
Capital Stock86.7 K48.6 K94.6 K
Very volatile
Net Working Capital185.5 M147.9 M129.3 M
Slightly volatile
Short Term Debt3.6 M4.1 M1.8 M
Slightly volatile
Common Stock219.8 K209.3 K55.3 K
Slightly volatile
Other Liabilities834.5 K1.1 M727.3 K
Slightly volatile
Non Current Liabilities Other905 K1.2 M742.7 K
Slightly volatile

Achilles Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.8 M5.4 M1.5 M
Slightly volatile
Selling General Administrative16.7 M19.6 M9.7 M
Slightly volatile
Other Operating Expenses58.4 M86.5 M33.4 M
Slightly volatile
Research Development43.7 M77.8 M25.1 M
Slightly volatile
Cost Of Revenue2.8 M5.4 M1.5 M
Slightly volatile
Total Operating Expenses58.4 M86.5 M33.4 M
Slightly volatile
Reconciled Depreciation2.7 M5.1 M1.4 M
Slightly volatile
Income Tax Expense592.9 K564.6 K246.8 K
Slightly volatile

Achilles Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation5.7 M5.4 M1.6 M
Slightly volatile
Capital Expenditures1.2 M1.3 M2.1 M
Slightly volatile
Total Cash From Financing Activities7.7 K8.1 K20.6 M
Very volatile
End Period Cash Flow157.2 M151.3 M78.2 M
Slightly volatile
Change To Netincome16.8 M16 M4.5 M
Slightly volatile
Stock Based Compensation5.1 M7.3 M2.6 M
Slightly volatile
Begin Period Cash Flow159.7 M199.4 M73.8 M
Slightly volatile
Issuance Of Capital Stock7.7 K8.1 K75.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio0.270.290.7295
Very volatile
Book Value Per Share3.894.118.9696
Slightly volatile
Capex To Depreciation0.250.272.3124
Very volatile
PB Ratio0.270.290.7295
Very volatile
Inventory Turnover0.50.720.6197
Pretty Stable
Days Of Inventory On Hand1.0E-41.0E-4495
Slightly volatile
Payables Turnover0.460.760.4462
Slightly volatile
Average Inventory1.8 M2.1 M2.3 M
Slightly volatile
Cash Per Share3.63.7816.6002
Slightly volatile
Days Payables Outstanding4744991 K
Slightly volatile
Income Quality0.990.80.9994
Slightly volatile
Net Debt To EBITDA4.042.072.5514
Slightly volatile
Current Ratio15.189.8511.9409
Pretty Stable
Tangible Book Value Per Share3.894.118.9697
Slightly volatile
Shareholders Equity Per Share3.894.118.9696
Slightly volatile
Debt To Equity0.03320.02920.0196
Slightly volatile
Capex Per Share0.03010.03160.0886
Slightly volatile
Graham Net Net3.293.4615.113
Slightly volatile
Interest Debt Per Share0.130.11550.2739
Slightly volatile
Debt To Assets0.02940.02570.0175
Slightly volatile
Operating Cycle1.0E-41.0E-4495
Slightly volatile
Price Book Value Ratio0.270.290.7295
Very volatile
Days Of Payables Outstanding4744991 K
Slightly volatile
Ebt Per Ebit1.060.91920.9924
Very volatile
Company Equity Multiplier0.891.021.0853
Slightly volatile
Total Debt To Capitalization0.03140.02830.0187
Slightly volatile
Debt Equity Ratio0.03320.02920.0196
Slightly volatile
Quick Ratio15.059.8511.8851
Pretty Stable
Net Income Per E B T0.80.910.9825
Slightly volatile
Cash Ratio13.868.910.3022
Slightly volatile
Days Of Inventory Outstanding1.0E-41.0E-4495
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.181.0968
Slightly volatile
Price To Book Ratio0.270.290.7295
Very volatile
Debt Ratio0.02940.02570.0175
Slightly volatile
Price Fair Value0.270.290.7295
Very volatile

Achilles Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap38.8 M40.9 M77.4 M
Pretty Stable

Achilles Fundamental Market Drivers

Cash And Short Term Investments131.5 M

Achilles Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Achilles Therapeutics Financial Statements

Achilles Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Achilles Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.1 M-4.8 M
Cost Of Revenue5.4 M2.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports:
How To Invest In Achilles
Details
Is Achilles Stock a good investment?
Details
What is Achilles Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Achilles Therapeutics Correlation against competitors.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.66)
Return On Assets
(0.30)
Return On Equity
(0.52)
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY